Dimensional Fund Advisors
PDLI

Dimensional Fund Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Dimensional Fund Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,318,552
Closed -$29.4M – 3409
2020
Q3 		$29.4M Sell
9,318,552
-285,167
-3% -$911K 0.01% 1620
2020
Q2 		$27.9M Sell
9,603,719
-17,340
-0.2% -$54.8K 0.01% 1666
2020
Q1 		$27.1M Buy
9,621,059
+90,110
+0.9% +$291K 0.01% 1545
2019
Q4 		$30.9M Sell
9,530,949
-681,283
-7% -$1.98M 0.01% 1800
2019
Q3 		$22.1M Sell
10,212,232
-835,029
-8% -$2.23M 0.01% 1949
2019
Q2 		$34.7M Sell
11,047,261
-996,145
-8% -$3.23M 0.01% 1731
2019
Q1 		$44.8M Sell
12,043,406
-409,715
-3% -$1.38M 0.02% 1527
2018
Q4 		$36.1M Sell
12,453,121
-160,323
-1% -$440K 0.02% 1581
2018
Q3 		$33.2M Buy
12,613,444
+98,954
+0.8% +$243K 0.01% 1824
2018
Q2 		$29.3M Buy
12,514,490
+996,690
+9% +$2.78M 0.01% 1881
2018
Q1 		$33.9M Buy
11,517,800
+1,129,428
+11% +$3.08M 0.01% 1720
2017
Q4 		$28.5M Buy
10,388,372
+1,680,911
+19% +$5.16M 0.01% 1857
2017
Q3 		$29.5M Buy
8,707,461
+1,279,431
+17% +$3.56M 0.01% 1803
2017
Q2 		$18.3M Buy
7,428,030
+1,744,380
+31% +$4.01M 0.01% 2075
2017
Q1 		$12.9M Buy
5,683,650
+1,401,470
+33% +$3.1M 0.01% 2210
2016
Q4 		$9.08M Buy
4,282,180
+582,265
+16% +$1.62M ﹤0.01% 2344
2016
Q3 		$12.4M Buy
3,699,915
+20,700
+0.6% +$65.7K 0.01% 2162
2016
Q2 		$11.6M Buy
3,679,215
+400,826
+12% +$1.34M 0.01% 2170
2016
Q1 		$10.9M Buy
3,278,389
+386,748
+13% +$1.21M 0.01% 2169
2015
Q4 		$10.2M Buy
2,891,641
+140,239
+5% +$587K 0.01% 2211
2015
Q3 		$13.8M Sell
2,751,402
-3,100
-0.1% -$17.8K 0.01% 2020
2015
Q2 		$17.7M Buy
2,754,502
+63,761
+2% +$427K 0.01% 1939
2015
Q1 		$18.9M Sell
2,690,741
-200
-0% -$1.45K 0.01% 1849
2014
Q4 		$20.7M Sell
2,690,941
-25,858
-1% -$205K 0.01% 1712
2014
Q3 		$20.3M Buy
2,716,799
+2,776
+0.1% +$25.8K 0.01% 1624
2014
Q2 		$26.3M Sell
2,714,023
-8,100
-0.3% -$72.2K 0.02% 1350
2014
Q1 		$22.6M Sell
2,722,123
-29,572
-1% -$253K 0.02% 1447
2013
Q4 		$23.2M Sell
2,751,695
-83,996
-3% -$708K 0.02% 1377
2013
Q3 		$22.6M Sell
2,835,691
-13,728
-0.5% -$110K 0.02% 1275
2013
Q2 		$22M Buy
+2,849,419
New +$22.2M 0.02% 1171

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors's PDLI Position: Q4 2020 in Review

Dimensional Fund Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 9,318,552 shares — an estimated $29.4M sold.

Dimensional Fund Advisors first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $44.8M in Q1 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Dimensional Fund Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Dimensional Fund Advisors sold 9,318,552 PDL BioPharma, Inc. shares in Q4 2020, an estimated $29.4M.
  • Dimensional Fund Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Dimensional Fund Advisors's PDL BioPharma, Inc. position peaked at $44.8M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Dimensional Fund Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.